Send to a Friend Font Size: Increase Decrease

RVMD and 4RY Related Headlines

Jun 30, 2025 08:07AM Revolution Medicines (RVMD) and Summit Therapeutics (SMMT) Enter Into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors With Ivonescimab in RAS Mutant Tumors
Jun 30, 2025 08:00AM Revolution Medicines and Summit Therapeutics Enter Into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors With Ivonescimab in RAS Mutant Tumors

RVMD and 4RY Related Press Releases

Jun 30, 2025 08:00AM Revolution Medicines and Summit Therapeutics Enter Into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors With Ivonescimab in RAS Mutant Tumors

RVMD and 4RY Related SEC Filings